Investigadores del CSIC evaluarán la eficacia de un anticuerpo monoclonal sintético contra el cáncer infosalus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from infosalus.com Daily Mail and Mail on Sunday newspapers.
Innate Pharma Shares Rise After AstraZeneca Presents Positive Data From NSCLC Trial to European Conference streetwisereports.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetwisereports.com Daily Mail and Mail on Sunday newspapers.
Innate Pharma Reports First Half 2021 Financial Results and Business Update apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory's Genome Engineering: CRISPR Frontiers Meeting marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Share this article Share this article POTENTIAL TREATMENT OF SEVERAL SOLID TUMOR CANCERS INCLUDING: NON-SMALL CELL LUNG CANCER, SQUAMOUS CELL CARNINOMA, BREAST CANCER, RENAL CANCER, PANCREATIC CANCER, OVARIAN CANCER, LIVER CANCER, COLORECTAL CANCER BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers. GTB-5550 TriKE™ was evaluated in several preclinical models overexpressing B7H3, and was found to be effective at promoting NK cell killing of multiple cancer cell types. B7H3 is over-expressed on several cancer types including non-small cell lung cancer, squamous cell carcinoma, and breast, renal, pancreatic, ovarian, liver and colorectal cancers. GTB-5550 TriKE™ is presently undergoing GMP manufacturing scale-up in preparation for filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for evaluation in humans.
Editas Medicine Announces Second Quarter 2021 Results and globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
INmune Bio, Inc. Announces Second Quarter 2021 Results and globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™ prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™ prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
'Global Catastrophe without Equal' — Expert Sounds the Alarm about MASS Vaccination freerepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freerepublic.com Daily Mail and Mail on Sunday newspapers.